A Phase 2 Study to Assess the Efficacy, Safety, and Pharmacodynamic Activity of PTC299 in Patients With Neurofibromatosis Type 2.
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2012
At a glance
- Drugs PTC 299 (Primary)
- Indications Cancer; Neurofibromatoses
- Focus Therapeutic Use
- 06 Apr 2012 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
- 07 Jun 2011 Planned End Date changed from 1 May 2011 to 1 May 2012 as reported by ClinicalTrials.gov.
- 07 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.